Moxifloxacin in the treatment of acute maxillary sinusitis after first-line treatment failure, and acute sinusitis with high risk of complications;Efficacité et tolerance de la moxifloxacine dans le traitement des sinusites maxillaires aiguës en situation d'échec et des sinusites à haut risque de complications

Medecine et Maladies Infectieuses

Volumn 32, Issue 9, 2002, Pages 494-507

  Gehanno, P ^a   Berche, P ^b   Perrin, A ^b  

^a BICHAT HOSPITAL   (France)

^b HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

Acute sinusitis; Frontal sinusitis; Ethmoid sinusitis; Maxillary sinusitis; Moxifloxacin; Pan sinusitis

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; BACAMPICILLIN; CEFACLOR; CEFADROXIL; CEFATRIZINE; CEFIXIME; CEFOTIAM HEXETIL; CEFPODOXIME PROXETIL; CEFUROXIME AXETIL; CLARITHROMYCIN; JOSAMYCIN; MOXIFLOXACIN; OXACILLIN; PENICILLIN DERIVATIVE; PRISTINAMYCIN; ROXITHROMYCIN; SPIRAMYCIN;

ABDOMINAL PAIN; ADULT; AGED; ANTIBIOTIC THERAPY; ARTHRALGIA; ARTICLE; ASTHENIA; BACTERIUM ISOLATE; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; ENTEROBACTERIACEAE; ERADICATION THERAPY; FEMALE; HAEMOPHILUS INFLUENZAE; HIGH RISK POPULATION; HUMAN; MALE; MAXILLA SINUSITIS; MORAXELLA CATARRHALIS; MULTICENTER STUDY; NAUSEA; NEUROTOXICITY; NONHUMAN; PERCEPTION DEAFNESS; RASH; SINUSITIS; STREPTOCOCCUS PNEUMONIAE; TACHYCARDIA; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 0036751497     PISSN: 0399077X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0399-077X(02)00414-6     Document Type: Article

References (26)

1. Gwaltney JM. Acute community-acquired sinusitis. Clin Infect Dis 1996;23:1209-25.
2. Barietti C, Jankowski R. Infections naso-sinusiennes aiguës de l'adulte. Etiologie, diagnostic, traitement. Rev Prat 1998;48:199-204.
3. Gehanno P, Berche P, the Sinusitis Study Group. Sparfloxacin versus cefuroxime axetil in the treatment of acute purulent sinusitis. J. Antimicrob Chemother 1996;37(Suppl A):105-14.
4. Henry DC, Sydnor A, Settipane GA, Allen JA, Burroughs S, Cobb MM, Holley HP. Comparison of cefuroxime Axetil and Amoxicillin/Clavulanate in the Treatment of Acute Bacterial Sinusitis. Clin. Ther 1999;21 july:1158-70.
5. Grollier G, Le Moal G, Robert R, Bernard C, Klossek JM. Rôle des bactéries anaérobies strictes dans les sinusites. Méd Mal Infect 2000;30(, Suppl 2):109-13.
6. Nord CE. The role of anaerobic bacteria in recurrent episodes of sinusitis and tonsillitis. CID 1995;20:1512-24.
7. Dabernat H, Delmas C. Activité du Centre National de Référence des Haemophilus influenzae, années 1996-1997 le déclin du type b. Méd Mal Infect 1998;28:940-6.
8. Bandak SI, Turnak MR, Allen BS, Bolzon LD, Preston DA, Bouchillon SK, Hoban DJ. Antibiotic Susceptibilities Among Recent Clinical Isolates of Haemophilus influenzae and Moraxella catarrhalis from Fifteen Countries. Eur J Clin Microbiol Infect Dis 2001;20:55-60.
9. Pean Y, Goldstein FW, Guerrier ML, le Groupe de Travail Français. Activité des antibiotiques sur Streptococcus pneumoniae, Haemophilus influenzae et Branhamella catarrhalis isolés infections respiratoires et ORL en rance: résultats une enquête multicentrique. Méd Mal Infect 1998;28:253-7.
10. Geslin P, Fremaux A, Sissia G. Evolution of résistance des pneumocoques responsables des infections des voies respiratoires en France. Méd Mal Infect 1992;22:74-86.
11. Sahm DF, Karlowski JA, Kelly LJ, Critchley LA, Jones ME, Thornsberry C, Mauriz Y, Kahn J. Need for Annual Surveillance of Antimicrobial Resistance in Streptococcus pneumoniae in the United-States: 2-year Longitudinal Analysis. Antimicrob Agents Chemother 2001;45(4):1037-42.
12. Baquero F, Garcia-Rodriguez JA, Garcia J, de Lomas L. Aguilar, and The Spanish Surveillance Group for Respiratory Pathogens. Antimicrobial resistance of 1113 Streptococcus pneumoniae isolates from patients with respiratory tract infections in Spain: results of a 1-year (1996-1997) multicenter surveillance study. Antimicrob Agents Chemother 1999;43:357-9.
13. Agence française de sécurité sanitaire des produits de santé. Antibiothérapie par voie générale en pratique courante. Sinusites aiguës de l'adulte, recommandations et argumentaires. Méd Mal Infect 2001;31 (suppl 4):493s-507s.
14. Siegert R, Gehanno P, Nikolaidis P, Bagger-Sjoback D, Ibanez JM, Hampel B, Sommerauer B, the Sinusitis Study Group. A comparison of the safety and efficacy of moxifloxacin and cefuroxime axetil in the treatment of acute bacterial sinusitis in adults. Respir Med 2000;94:337-44.
15. Burke T, Villanueva C, Mariano Jr H, Huck W, Orchard D, Haverstock D. Comparison of moxifloxacin and cefuroxime axetil in the treatment of acute maxillary sinusitis. Sinusitis Infection Study Group. Clin Ther 1999;21(10):1664-77.
16. Adelgass J, DeAbate CA, McElvaine P, Fowler CL, LoCocco J, Campbell T. Comparison of the effectiveness of levofloxacin and amoxicillin-clavulanate for the treatment of acute sinusitis in adults. Otolaryngol Head Neck Surg 1999;120(3):320-7.
17. Fish DN, North DS. Gatifloxacin, and Advanced 8-Methoxy Fluoroquinolone. Pharmacotherapy 2001;21(1):35-59.
18. Penttila M, Savolainen S, Kiukaanniemi H, Forsblom B, Jousimies-Somer H. Bacterial findings in acute maxillary sinusitis-European study. Acta Otolaryngol Suppl 1997;529:165-8.
19. Axelsson A, Chidekel N. Symptomatology and bacteriology correlated to radiological findings in acute maxillary sinusitis. J Otolaryngol 1972;74(1):118-22.
20. Gehanno P, Barry B, Chauvin JP, Hazebroucq J. Clarithromycin versus amoxicillin-clavulanic acid in the treatment of acute maxillary sinusitis in adults. Pathol Biol (Paris) 1996;44(4):293-7.
21. Clifford K, Huck W, Shan M, Tosiello R, Echols RM, Heyd A. Double-blind comparative trial of ciprofloxacin versus clarithromycin in the treatment of acute bacterial sinusitis. Sinusitis Infection Study Group. Ann Otol Rhinol Laryngol 1999;108(4):360-7.
22. Gwaltney Jr JM, Scheld WM, Sande MA, Sydnor A. The microbial etiology and antimicrobial therapy of adults with acute community-acquired sinusitis: a fifteen-year experience at the University of Virginia and review of other selected studies. J Allergy Clin Immunol 1992;90(3 Pt 2):457-61 discussion 462.
23. Gehanno P, Darantière S, Dubreuil C, Chobaut JC, Bobin S, Pages JC, Renou G, Bobin F, Arvis P, Stass H. A prospective, multicentre study of moxifloxacin concentrations in the sinus mucosa tissue of patients undergoing elective surgery of the sinus. J Antimicrob Chemother 2002;49:821-6.
24. Paavolainen M, Kohonen A, Palva T, Renkonen AV. Penetration of erythromycin stearate into maxillary sinus mucosa and secretion in chronic maxillary sinusitis. Acta Otolaryngol (Stockholm) 1997;84:292-5.
25. Wise R. A Review of the Clinical Pharmacology of Moxifloxacin, a New 8-Methoxyquinolone, and its Potential Relation to Therapeutic Efficacy. Clin Drug InvestMay 1999;17(5):365-87.
26. e ECCMID, 24-27 Avril, Milan. 2002 Abstract N° P1380.